It is also unknown whether the heterogeneity of TDP-43 pathology (subtypes A-C) and FTLD-tau (PiD, CBS, PSP) can be disaggregated at the biochemical level. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.